A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma

Trial Profile

A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Melphalan (Primary)
  • Indications Liver metastases; Uveal melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms FOCUS
  • Sponsors Delcath Systems
  • Most Recent Events

    • 11 Nov 2016 According to Delcath media release, company has expanded this trial to include 10 new research centers in the U.S. and Europe.
    • 18 Oct 2016 According to a Delcath Systems media release, the company is on track to complete enrollment in mid-2018 with the potential for a pre-specified interim analysis around the end of 2017.
    • 20 Jan 2016 Status changed from planning to recruiting, according to a Delcath media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top